Analysing the expression of potent kinase off-targets of PARP inhibitors in haematological cancers using canSAR53 reveals that DYRK1A and DYRK1B are overexpressed at the mRNA level in several types of leukaemia and lymphoma (Supplementary Figs. 3–6). The gene discussed is PARP1; the disease is leukemia.